# Director — Wave 0/1 coordination log

Role: `flow-director` (research director/reconciler). This file records only Wave 0/1 coordination
activity — sent-message matrix and specialist replies. No synthesis, no numbered deliverables, no
`SOURCE_LEDGER.csv` here or elsewhere in this wave, per `CLAUDE.md` and `orchestration/ORCHESTRATION.md`.

Note on provenance: this session is background-isolated in git worktree `flow-director-wave0`
(branch `worktree-flow-director-wave0`) per harness policy for background sessions. This file is
committed/pushed from that worktree; it should be merged into the shared working tree alongside the
other specialists' lane files during Wave 3 reconciliation (each specialist appears to be working in
its own similarly isolated worktree — e.g. `ckm-combinations-lane`, `endocrinology-lane`,
`trialist-stats-lane` were already present under `.claude/worktrees/` at Wave 0 dispatch time).

## Context read before dispatch

- `CLAUDE.md` (project instructions / non-negotiable evidence rules / file contract)
- `Semaglutide ckd and flow evidence prompt.md` (master prompt)
- `research/semaglutide_ckd_flow/2026-09-05/orchestration/ORCHESTRATION.md` (roles, wave sequence, message protocol)
- `research/semaglutide_ckd_flow/2026-09-05/orchestration/SESSION_LOG.md` (session UUIDs, Wave 1 state = "launched" for all six specialists as of dispatch)
- `research/semaglutide_ckd_flow/2026-09-05/orchestration/prompts/01-06_*.md` (role prompts, headers only)

At dispatch time, `lanes/` was empty (no Wave 1 memos yet written) in the main checkout.

## Sent-message matrix (Wave 0 CROSS_SESSION_TEST)

| # | Recipient session | ListAgents ref | Owned Wave 1 path | msg_id | Sent | Reply received |
|---|---|---|---|---|---|---|
| 1 | `flow-source-librarian` | `e04063` | `lanes/01_source_librarian.md` | `a8e46a7f-adb3-4b0b-9b36-75681c43c8b0` | ✅ | ✅ received |
| 2 | `flow-trialist` | `31743f` | `lanes/02_trialist_statistics.md` | `198ca981-c96e-4ce2-854a-877fa59f112a` | ✅ | ✅ received |
| 3 | `flow-nephrologist` | `c77be6` | `lanes/03_nephrology.md` | `f33a377f-96b3-4994-994e-f386c2db0998` | ✅ | ✅ received |
| 4 | `flow-endocrinologist` | `5d09cb` | `lanes/04_endocrinology.md` | `142bdc1b-9946-48bb-b187-3d459fd26eea` | ✅ | ✅ received |
| 5 | `flow-ckm` | `be1796` | `lanes/05_ckm_combinations.md` | `b543368a-2c45-46cb-88e4-20ad5a4fc7ef` | ✅ | ✅ received |
| 6 | `flow-methodologist` | `b4cc2f` | `lanes/06_methods_mechanisms.md` | `8ec02c50-d55a-40ba-ab78-42d33ff7c99b` | ✅ | ✅ received |

Each message asked for: (1) READY confirmation against CLAUDE.md / master prompt / ORCHESTRATION.md / own role
prompt; (2) confirmation of owned Wave 1 output path (plus any role-prefixed `sources/retrieved/` notes);
(3) single highest-priority uncertainty or conflict so far. Each also instructed the specialist to resume/finish
its Wave 1 memo after replying, and reiterated the director-only restriction on numbered deliverables 01-16 and
`SOURCE_LEDGER.csv`. All six sessions showed `bg · busy` in `ListAgents` at send time, consistent with active
Wave 1 work already in progress.

## Replies log

### `flow-trialist` (received)

- **READY:** Yes — confirms reading CLAUDE.md, master prompt, ORCHESTRATION.md, role prompt
  `02_trialist_statistics.md`.
- **Path:** Confirmed `lanes/02_trialist_statistics.md`. No `sources/retrieved/` note planned yet (FLOW data
  taken from local fulltext); may add one later only if pulling CREDENCE/DAPA-CKD/EMPA-KIDNEY/FIDELIO primary
  numbers from the web for a contextual comparison table.
- **Highest-priority issue (data quality, not a numeric conflict):**
  `fulltext/FLOW_primary_NEJM_2024_fulltext.md` Table 2 (efficacy/safety outcomes table, journal p.116) is
  extracted as mirrored/character-reversed text — unusable as-is. Trialist self-resolved by reading
  `fulltext/FLOW.pdf` page 8 directly (image) and transcribing Table 2 cleanly. Flags for other lanes and the
  librarian: anyone quoting FLOW Table 2 component-level numbers (initiation of kidney-replacement therapy 87
  vs 100; persistent eGFR<15 92 vs 110; persistent ≥50% eGFR reduction 165 vs 213; death from kidney-related
  causes 5 vs 5) from the `.md` extraction should re-verify against the PDF page image rather than trust the
  `.md` for that table. No other numeric conflicts found yet.
- **Action for director:** relay this data-quality flag to `flow-source-librarian` (owns source
  inventory/fulltext integrity) so the ledger notes the Table 2 extraction defect and the correct-transcription
  values trialist already recovered — done below (see "Director actions this turn").

### `flow-endocrinologist` (received)

- **READY:** Yes — confirms reading CLAUDE.md, master prompt, ORCHESTRATION.md, role prompt
  `04_endocrinology.md`.
- **Path:** Confirmed `lanes/04_endocrinology.md`. No `sources/retrieved/` notes planned yet (citing primary
  journal articles inline with DOI/PMID); will add a role-prefixed note only if a source worth preserving
  verbatim turns up (e.g. paywalled abstract-only extraction).
- **Highest-priority uncertainty:** The SUSTAIN-6/LEADER pooled GLP-1RA kidney-mediation analysis (Mann et al.,
  *Diabetes Obes Metab* 2021, DOI 10.1111/dom.14443) reports HbA1c mediates ~25-26% and systolic BP ~9-22% of
  the kidney-composite effect — a meaningfully large mediated fraction that cuts against a strong
  "independent of glycemia/BP" claim for the pre-FLOW signal. Yet FLOW's own discussion (citing this same
  mediation work) argues effects were "unrelated to changes in body weight" and consistent whether eGFR is
  creatinine- or cystatin-C-based. No semaglutide-specific (vs pooled semaglutide+liraglutide) mediation
  breakdown found yet, and no FLOW-specific mediation analysis for HbA1c/weight/BP. Endocrinology lane will
  grade this as suggestive-at-best pre-FLOW and largely unknown/unquantified for FLOW itself pending a
  FLOW-specific mediation paper. Flags possible overlap with nephrology (03) and methods/mechanisms (06) lanes
  chasing the same source — risk of duplicated work or conflicting mediation-strength language at Wave 2.
- **Action for director:** relay this overlap flag to `flow-nephrologist` and `flow-methodologist` so they can
  coordinate on mediation-strength language before Wave 2 — done below (see "Director actions this turn"). This
  is directly relevant to CLAUDE.md rule 7 (no inferring causally independent glucose/weight/BP-mediated
  effects from subgroup consistency alone) — will need explicit attention at Wave 3 reconciliation.

### `flow-nephrologist` (received)

- **READY:** Yes — confirms reading CLAUDE.md, master prompt, ORCHESTRATION.md, role prompt
  `03_nephrology.md`. Also read the FLOW primary (NEJM 2024) fulltext + Supplementary Appendix in full, plus
  Mann 2024 (SGLT2i), Mahaffey 2025 (CV-by-CKD-severity), Rossing 2025 (MRA) fulltexts; skimmed Neuen 2024
  (modeled combination therapy) and Sawami 2024 (narrative review).
- **Path:** Confirmed `lanes/03_nephrology.md` only. No `sources/retrieved/` note planned yet (working from
  local `fulltext/`); will add a role-prefixed note only if pulling something not already local (e.g.
  eGFR<25/dialysis/non-diabetic-CKD claims).
- **Highest-priority uncertainty:** Independently hit the same FLOW Table 2 OCR-scramble that `flow-trialist`
  reported (columns/rows out of order, text reversed, roughly lines 480-850 of
  `fulltext/FLOW_primary_NEJM_2024_fulltext.md`). Can confidently confirm composite-level numbers (primary
  composite 331/410; kidney-specific 4-component composite HR 0.79 [0.66-0.94]; CV death alone HR 0.71
  [0.56-0.89]; CV death ≈35% of primary-composite events per Supplement Table S2 note) but declined to guess
  per-component n's from garbled OCR. Attempting a clean re-extraction from `fulltext/FLOW.pdf` Table 2
  (page ~116) directly; if unresolved will file an explicit GAP in the lane memo for the trialist to
  re-verify. **Cross-check:** this independently corroborates trialist's per-component numbers already
  relayed to the librarian (kidney-replacement therapy 87 vs 100; persistent eGFR<15 92 vs 110; persistent
  ≥50% eGFR reduction 165 vs 213; kidney death 5 vs 5) — two lanes now converge on the same PDF-page
  transcription route and the same composite-level figures, which is reassuring for those numbers.
- **Follow-up ack (after relay):** Nephrologist acknowledges the endocrinology mediation-analysis relay.
  FLOW's own Discussion (NEJM 2024;391:109, citing Mann et al. 2021 as ref 11) says kidney/CV risk-factor
  changes were "only modestly mediated" — not a body-weight-specific mediation analysis, and not
  FLOW-specific quantification. Nephrology will grade the "independent of glycemia/weight/BP" claim as
  suggestive-at-best / not formally quantified for FLOW itself in `lanes/03_nephrology.md`, consistent with
  CLAUDE.md rule 7, and will flag it explicitly as a cross-lane item for Wave 2 rather than asserting
  independence. No duplicate retrieval planned.

### `flow-ckm` (received)

- **READY:** Yes — confirms reading CLAUDE.md, master prompt, ORCHESTRATION.md, role prompt
  `05_ckm_combinations.md`.
- **Path:** Confirmed `lanes/05_ckm_combinations.md` only. Core evidence (FLOW primary NEJM+supplement, Mann
  2024 SGLT2i subgroup, Rossing 2025 MRA subgroup, Mahaffey 2025 CV-by-CKD-severity, Neuen 2024
  lifetime-modeling, Sawami 2024 review) already in `fulltext/`; supplementing with WebSearch/WebFetch for
  current guideline/regulatory items. Will add a `ckm`-role-prefixed retrieved note only if a new full source
  is pulled.
- **Highest-priority uncertainty:** Several 2026 current-source items could not be independently
  quote-verified this session because primary-document fetches were blocked (403 / undecompilable PDF):
  (1) **KDIGO 2026 Diabetes+CKD guideline** — corroborated via kdigo.org as a March 2026 public-review draft,
  comment period closed 2026-04-13; no confirmed final-publication date as of 2026-09-05 — treating as
  DRAFT-ONLY, not quoting exact recommendation text. (2) **ADA Standards of Care 2026 CKD chapter**
  (rec. 11.7b / 9.10-9.11) — content triangulated via secondary summaries only; exact wording NOT
  independently confirmed (diabetesjournals.org fetch blocked). (3) **2026 AHA/ACC/ADA/ASN CKM guideline** —
  confirmed published (JACC, DOI 10.1016/j.jacc.2026.03.056, June 9 2026) but exact sequencing/layering
  recommendation text for RASi+SGLT2i+finerenone+GLP-1RA not independently retrievable (fetch blocked). Will
  flag all three as unverified-wording (not asserting quotes) for the librarian/red-team to chase primary-text
  confirmation. No blocking numerical conflicts against other lanes yet (none had written memos at reply
  time).
- **Director note:** this is a verification-access gap, not a numeric conflict — appropriate for
  `flow-source-librarian` to track and for Wave 5 red-team to re-attempt with different fetch routes before
  any CKM-guideline-sequencing claim is finalized at Wave 3.

### `flow-source-librarian` (received)

- **READY:** Yes — confirms reading CLAUDE.md (including an on-disk update received mid-Wave-0 adding the
  `research_hub`/`paper-search`/`google-scholar` MCP preference, a no-Sci-Hub rule, and the
  `sources/retrieved/cache/` convention — see note below), the full master prompt, ORCHESTRATION.md, and role
  prompt `01_source_librarian.md`.
- **Path:** Confirmed `lanes/01_source_librarian.md` — **written and complete this turn** (source inventory
  table with stable IDs, claim-support mapping, exact local FLOW-number locators, draft `SOURCE_LEDGER.csv`
  row block, missing/inaccessible sources + bibliographic inconsistencies, review/editorial exclusion list,
  handoff summary). No `sources/retrieved/` notes added — no PDFs downloaded/cached this turn; web
  verification was bibliographic-only (paper-search MCP / CrossRef / PubMed / Europe PMC / WebSearch, no
  Sci-Hub). Incorporated the director's Table 2 OCR-scramble relay and the trialist's transcribed component
  counts into lane §5, attributed to `flow-trialist`/`flow-nephrologist` pending their own clean
  re-verification.
- **Highest-priority uncertainty:** `SELECT-FLOW-SOUL-POOLED-2026` (*Lancet Diabetes Endocrinol* 2026, DOI
  10.1016/S2213-8587(26)00134-8, "Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL
  trials: a prespecified pooled analysis") — bibliographic identity (title/authors/DOI) confirmed verbatim via
  CrossRef and matches the master prompt, but abstract/results not retrievable this session (no volume/page
  yet, consistent with very recent online-first). Flagged as a master-prompt "high-priority current source"
  for Section V; librarian can vouch only for bibliographic identity, not the numbers — whoever owns that
  content (trialist or methodologist) should fetch full text before Wave 3.
- **Note on mid-Wave-0 CLAUDE.md update:** `CLAUDE.md` changed on disk after this director's Wave 0 dispatch,
  adding: MCP source-discovery preference (`research_hub`/`paper-search`/`google-scholar` first;
  `openevidence` orientation-only, never a primary-source substitute); an explicit no-Sci-Hub rule; a
  `sources/retrieved/cache/` (gitignored) convention for downloaded PDFs/parses, with only metadata/provenance/
  short notes going to the public repo; an API-key handling rule for the LlamaParse MCP; and `llamaparse`
  restricted to lawfully-obtained PDFs with route/license recorded. This session (director) is now working
  under the updated file. Flagging for the record since it postdates this director's original Wave 0
  dispatch messages — worth a quick note to any lane that already downloaded/cached a PDF before the update
  landed, to confirm its storage location and route documentation are compliant. Not treating this as
  something to "undo" — per system guidance, it's the current, deliberate state.

### `flow-trialist` (follow-up on `SELECT-FLOW-SOUL-POOLED-2026` relay)

- Declines ownership: lane `02_trialist_statistics` is scoped strictly to FLOW trial anatomy/endpoints/
  statistics per role brief; the SELECT/FLOW/SOUL pooled post-FLOW analysis is out of scope. Noted
  "outstanding, owned by flow-methodologist" in its lane file for reconciliation visibility. **Wave 1 lane
  memo (`lanes/02_trialist_statistics.md`) is now complete.**
- **Director action:** sent `flow-methodologist` a follow-up confirming sole ownership of
  `SELECT-FLOW-SOUL-POOLED-2026` by default — no further coordination needed with trialist on this item.

### `flow-methodologist` (received — 6th and final Wave 0 reply)

- **READY:** Yes — confirms reading CLAUDE.md, master prompt, ORCHESTRATION.md, role prompt
  `06_methods_mechanisms.md`.
- **Path:** Confirmed `lanes/06_methods_mechanisms.md` — **written, committed, and pushed** on branch
  `worktree-flow-methodologist-lane06` (confirms the same per-session worktree-isolation pattern this director
  is using). Retrieved-source note added at `sources/retrieved/methodologist_web_sources_2026-09-05.md`
  (role-prefixed; documents route/access status for 5 non-local sources: Badve 2025, Pyke 2014, Hinrichs 2024,
  Mann 2021, and the SELECT/FLOW/SOUL 2026 pooled analysis).
- **Highest-priority item — now resolved, not open:** independently retrieved Mann et al. 2021 full text
  (PMC8453827, DOI 10.1111/dom.14443) and resolved the mediation-analysis flag relayed earlier from
  endocrinology/nephrology. Exact figures: HbA1c mediated 25% (LEADER, 95% CI −7.1 to 67.3) / 26% (SUSTAIN-6,
  CI noncalculable); systolic BP 9% (LEADER, CI 2.8–22.7) / 22% (SUSTAIN-6, CI noncalculable); body weight 9%
  (LEADER, CI −7.9 to 35.5) / 0% (SUSTAIN-6 — no detectable mediation in the semaglutide-specific arm). Source
  paper's own conclusion is "only a modest portion" (FLOW's paraphrase not inaccurate), but point estimates too
  large / CIs too wide/noncalculable to license an unqualified "independent of glycemia" claim — graded
  **suggestive**, not strongly supported, in §3/§6/§7. Explicit caveat: this is a LEADER/SUSTAIN-6 pooled
  analysis with a **different (CV-death-excluded) kidney composite than FLOW's own** — not a FLOW-specific
  mediation analysis. Requested the director relay the exact numbers (not FLOW's one-line paraphrase) to
  endocrinology and nephrology — **done this turn** (see Director actions below).
- **Also picked up `SELECT-FLOW-SOUL-POOLED-2026`** after trialist declined it: retrieved a structured abstract
  via `mcp__paper-search__search_pubmed` (PMID 42567173, cross-confirmed via CrossRef, no Sci-Hub). Key
  numbers (abstract-level only, full tables/appendix not retrieved): pooled N=30,787; primary kidney composite
  973 vs 1,134 events, HR 0.84 (95% CI 0.77–0.91); kidney-specific (CV-death-excluded) composite 347 vs 416
  events, HR 0.80 (0.69–0.92). Graded the abstract's own "not explained only by glycaemic/weight effects"
  claim as hypothesis-generating (cross-trial-consistency argument), while treating the HRs themselves as
  established pooled-RCT evidence. Flagged for lane 02/trialist to cross-check independently if full text is
  retrieved — relayed this turn (see Director actions below; optional/FYI given trialist's lane is already
  complete).
- Confirms not touching 01-16 or `SOURCE_LEDGER.csv`. Notes it is standing by for Wave 2 (peer cross-review per
  ORCHESTRATION.md) — **not actioned by the director this turn**; Wave 2 pairing assignment is out of scope
  for this Wave 0/1 coordination task and will be handled separately.

### Follow-up acks (post-relay, both received)

- **`flow-nephrologist`:** incorporated the resolved Mann 2021 figures into `lanes/03_nephrology.md` §2.5 and
  §7.4, cited with the composite-definition caveat, graded suggestive/not-strongly-supported, noted as
  second-hand (via director relay from methodologist, not independently verified by this lane). Flag closed;
  nothing further needed before Wave 2.
- **`flow-trialist`:** staying within declared scope — not retrieving the SELECT-FLOW-SOUL pooled full text
  itself (methodologist owns it). Added a short cross-reference note to `lanes/02_trialist_statistics.md`
  relaying the abstract-level numbers for Wave 3 traceability, explicitly marked methodologist-owned/not
  independently verified, with a suggestion that whoever writes deliverables 14/15 get one independent
  full-text check before treating the pooled HR as headline-load-bearing (abstract-only sourcing is
  provisional per CLAUDE.md). Pushed as commit `6065ece` on `worktree-trialist-stats-lane`. Lane memo
  otherwise unchanged and complete.

### `flow-endocrinologist` — lane complete

- Incorporated the relayed Mann 2021 figures into source table, pre-FLOW arc section, and the glycemia/weight/
  BP independence-grading table in `lanes/04_endocrinology.md` (exact percentages + composite-definition
  caveat); closed that item in its own unresolved-conflicts log.
- **`lanes/04_endocrinology.md` is now complete**: cross-trial arc (SUSTAIN-6/PIONEER-6 → FLOW → SELECT/SOUL →
  FLOW-CKD-severity), SOUL-vs-FLOW divergence explanation, SELECT's glucose-independence limits, the
  HbA1c/weight/BP independence grading table, "compelling at HbA1c goal" section, obesity/ASCVD/glycemic
  phenotype positioning, CKD-specific safety (retinopathy/hypoglycemia/GI/AKI/gallbladder-pancreatitis/
  gastroparesis/dialysis gap), and five evidence-graded patient vignettes (A-E) with nephrology-sensitive
  caveats.
- **Flags for Wave 3:** (1) no usable numbers from `SELECT-FLOW-SOUL-POOLED-2026` — correctly deferred, per
  this director's Wave 0 relay, to trialist/methodologist ownership; nothing cited from it. (2)
  `FLOW-CKD-SEVERITY-2026` (PMID 41706532, likely the JACC 2026 CV-by-CKD-severity subgroup paper from master
  prompt §III.8) is abstract-level only on endocrinology's end, exact journal/volume/page unconfirmed —
  possible overlap with "Mahaffey 2025 (CV-by-CKD-severity)," which both `flow-nephrologist` and `flow-ckm`
  independently cited from local `fulltext/` in their Wave 0 replies.
- **Director action:** relayed the citation-reconciliation question — is `Mahaffey 2025` the same paper as
  `FLOW-CKD-SEVERITY-2026`/PMID 41706532? — to both `flow-nephrologist` and `flow-ckm`, asking whichever has
  a clean local citation to confirm/supersede endocrinology's abstract-level one before Wave 3.

### Resolution: three distinct FLOW subgroup-analysis papers (superseded once, now settled)

Initial pass (from `flow-nephrologist`) suggested two distinct papers with a tentative, unconfirmed PMID→DOI
guess. `flow-ckm` then independently verified (WebSearch + PubMed record + CJASN publisher page + Healio + an
institutional research-portal record — 4 independent sources agreeing) that there are **three** distinct
papers, and corrected the PMID mapping. Settled state:

1. **Mahaffey 2025** (held locally by nephrology + CKM, `fulltext/glp1_cardiorenal_Mahaffey_2025.md`, the only
   one of the three fulltext-verified this session): Mahaffey KW, Tuttle KR, Arici M, et al. "Cardiovascular
   outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial."
   *European Heart Journal* 2025;46(12):1096–1108. DOI 10.1093/eurheartj/ehae613. PMID 39211948. Master prompt
   III.5; CV composite + all-cause mortality, stratified by eGFR/UACR/KDIGO risk.
2. **PMID 41706532 = CJASN 2026 (endocrinology's actual source, master prompt III.8)** — NOT the JACC paper as
   first guessed: Tuttle KR, Mann JFE, Mayrdorfer MM, et al. "Kidney and Survival Outcomes with Semaglutide by
   CKD Severity in the FLOW Trial." *Clinical Journal of the American Society of Nephrology (CJASN)*
   2026;21(5):841–851 (online 2026-02-18). DOI appears to be 10.2215/CJN.0000000974 (seen in a URL slug —
   **unverified against the DOI resolver, flagged for librarian**). Kidney composite + all-cause death by
   eGFR/albuminuria strata.
3. **`FLOW-CVPHENOTYPE-2026`** (CKM's source, held only at abstract level): "Kidney and Survival Benefits of
   Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses." *JACC*
   2026. DOI 10.1016/j.jacc.2026.02.5125. **PMID 42233552** (this, not 41706532, is the JACC paper's PMID).
   Stratifies by CV phenotype (ASCVD/HF/no-CVD-high-PREVENT-risk).

- **Director actions:** relayed the corrected three-paper mapping to `flow-endocrinologist` (keep PMID
  41706532 but fix journal/DOI to CJASN, not JACC), `flow-nephrologist` (their JACC guess pointed at the wrong
  second paper — the "different paper" instinct was right), and `flow-source-librarian` (track all three as
  separate ledger rows, #2's DOI needs resolver verification, #2 and #3 are candidates for a full-text pull).
  Acknowledged `flow-ckm`'s verification and confirmed no further action needed on their end.
- **Follow-up acks:** `flow-nephrologist` confirms its lane file never actually cited either the CJASN or JACC
  paper by name (only speculated about the match in a cross-session reply, not in `lanes/03_nephrology.md`
  itself) — so no correction needed to that lane file. `flow-ckm` acknowledged the loop is closed.
- **CJASN DOI now confirmed:** `flow-source-librarian` verified 10.2215/CJN.0000000974 via doi.org redirect +
  exact CrossRef metadata match (vol 21, issue 5, pp. 841–851, 2026-02-18) and pulled abstract-level numbers
  (primary composite HR 0.76 [0.66–0.88]; all-cause death HR 0.80 [0.67–0.95]; consistent across eGFR/UACR
  strata; an exploratory UACR≥2000-mg/g death-HR subgroup finding, HR 0.47, P-interaction 0.02 — flagged
  exploratory-only per CLAUDE.md rule 5). Tracked by librarian as `FLOW-CKDSEVERITY-2026-CJASN` (master prompt
  III.7). Full text still not obtained (CJASN direct fetch hit HTTP 402 paywall) — abstract-level only.
  Relayed to `flow-endocrinologist` (update citation to CJASN + these numbers, abstract-level caveat) and
  `flow-nephrologist` (FYI, may be useful for advanced-CKD/UACR context).
- **Closed:** `flow-endocrinologist` confirmed the citation fix is applied — `FLOW-CKDSEVERITY-2026-CJASN`
  finalized as Tuttle et al., CJASN 2026;21(5):841-851, DOI 10.2215/CJN.0000000974, with the librarian's
  numbers incorporated (and a useful catch: the abstract's 331/1767 vs 410/1766 primary-composite and
  227/1767 vs 279/1766 mortality counts are **identical to FLOW-primary's own overall counts** — i.e. this
  CJASN paper restates FLOW's headline result stratified by CKD severity, not a separate cohort). Committed as
  `8c2dcf0` on endocrinology's lane branch. **`lanes/04_endocrinology.md` is fully complete and ready for
  Wave 2** per the author.
- Full text of the CJASN paper remains unobtained (402 paywall) — abstract-level sourcing persists as the
  ceiling for this source pending any future full-text pull.

### `SELECT-FLOW-SOUL-POOLED-2026` — independently corroborated, one open sub-gap

`flow-endocrinologist` (via a spawned sub-scout) independently retrieved the same structured abstract through
**Europe PMC's DOI lookup** (PMID 42567173) rather than CrossRef/direct journal fetch — numbers match
`flow-methodologist`'s exactly (pooled N=30,787; primary composite HR 0.84 [0.77–0.91]; kidney-specific
composite HR 0.80 [0.69–0.92]). Two independent retrieval routes now agree at the abstract level; full text
and I²/forest-plot data remain unobtained. Director relayed this corroboration + the Europe PMC route to
`flow-methodologist` and `flow-trialist`. `flow-trialist` acknowledged but is intentionally not touching its
lane file this turn (scoped to `cross_reviews/` only per its current task) — notes the second-source
confirmation can be folded in at Wave 3/by the director when compiling deliverables 14/15.

**Separately flagged by endocrinology, still open:** SUSTAIN-6's exact hard-component (creatinine-doubling/
RRT/renal-death) event counts are unresolved — NEJM stayed 403-paywalled to every retrieval attempt tried so
far; needs institutional access. Not relayed further this turn (no obvious lane owner beyond
endocrinology/librarian); flagging here for Wave 3 visibility.

### Wave 2 has begun organically (ahead of formal director dispatch)

`flow-trialist` completed its Wave 2 peer review of nephrology per the **fixed pairing already specified in
`ORCHESTRATION.md`** (trialist reviews nephrology) — `cross_reviews/02_trialist_reviews_nephrology.md`,
committed `c492125` on `worktree-trialist-stats-lane`. This was not dispatched by the director (Wave 2
assignment was explicitly out of scope for this Wave 0/1 turn) — the specialist self-initiated once its own
lane was complete, using the roles table already published in `ORCHESTRATION.md`.

Highlights: (1) FLOW Table 2 now double-verified byte-identical by two independent extraction methods
(nephrology's `pdftotext -layout` vs. trialist's PDF page-image read) — trialist recommends treating it as
fully resolved. (2) **Correction with exact replacement wording:** nephrology §6.2 mislabels the AE-driven
discontinuation figures (233/211, Table 3) as "overall" discontinuation; true any-reason discontinuation is
26%/28.8% — relayed to `flow-nephrologist` this turn. (3) Trialist independently re-confirmed via Fig. 2 that
eGFR/UACR subgroup interaction P-values are genuinely absent from the primary publication/supplement (not just
a local-extraction gap) — recommends nephrology close that GAP rather than reassign it, also relayed. (4)
Two items flagged for Wave 3 without director action needed now: a three-way CV-death-share arithmetic
discrepancy (39.4% pooled vs 41.2%/37.2% per-arm vs "~35%" in-source — not previously caught by either lane),
and Mann JFE 2021's mediation point estimates remaining second-hand for both trialist and nephrology (neither
has independently verified that source's numbers, despite methodologist having done so — worth noting at
Wave 3 that the primary verification sits with methodologist, not the two lanes now citing it).

**Director note for the record:** since Wave 2 is starting on its own initiative using the pre-published
fixed assignments, this director session has treated peer-review-content relays (like the discontinuation
correction above) the same way as Wave 1 cross-lane relays — naming exact files/locators, not adjudicating.
Whether to formally dispatch the remaining Wave 2 pairs (endocrinology↔CKM, methodologist on combinations,
librarian auditing citations) or let them arise organically as lanes complete is an open question for this
session's next resumption / the user's guidance.

## Director actions this turn

1. Relayed `flow-trialist`'s FLOW Table 2 extraction-defect flag to `flow-source-librarian` (own the source
   inventory/fulltext integrity) with the corrected component-level numbers, so the ledger can note the
   `.md` extraction defect and point lane authors to the PDF page image. (`flow-nephrologist`'s independent
   corroboration of the same defect, received after the relay was sent, is noted above but not yet
   re-relayed — low priority since it confirms rather than changes the librarian's action item.)
2. Relayed `flow-endocrinologist`'s mediation-analysis overlap flag to `flow-nephrologist` and
   `flow-methodologist` so they can coordinate mediation-strength language ahead of Wave 2 and avoid
   duplicated retrieval of Mann et al. 2021 (DOI 10.1111/dom.14443). `flow-nephrologist` acknowledged and
   will grade consistently with CLAUDE.md rule 7 (see above).
3. Relayed `flow-source-librarian`'s `SELECT-FLOW-SOUL-POOLED-2026` fulltext gap (DOI
   10.1016/S2213-8587(26)00134-8 — bibliographic identity confirmed, results not yet retrieved) to both
   `flow-trialist` and `flow-methodologist`, asking them to coordinate so only one lane chases the full text
   before Wave 3 and the other notes it as outstanding/owned-by-peer.
4. After `flow-trialist` declined (out of scope) and named `flow-methodologist` as owner in its lane file,
   sent `flow-methodologist` a follow-up confirming sole ownership by default — closed that coordination loop
   without director adjudication.
5. On receiving `flow-methodologist`'s resolved Mann et al. 2021 mediation figures, relayed the exact numbers
   (HbA1c 25%/26%, SBP 9%/22%, weight 9%/0% by trial, with CIs and the CV-death-excluded-composite caveat) to
   `flow-endocrinologist` and `flow-nephrologist`, instructing both to cite the figures directly rather than
   FLOW's paraphrase — closes the mediation-analysis coordination loop opened at item 2.
6. Relayed `flow-methodologist`'s `SELECT-FLOW-SOUL-POOLED-2026` structured-abstract numbers (N=30,787;
   primary kidney composite HR 0.84 [0.77–0.91]; kidney-specific composite HR 0.80 [0.69–0.92]; PMID 42567173)
   to `flow-trialist` as an optional cross-check, explicitly not reopening trialist's earlier scope decision.
7. On `flow-endocrinologist` reporting completion, relayed its `FLOW-CKD-SEVERITY-2026`/PMID 41706532 citation
   gap and its possible identity with "Mahaffey 2025 (CV-by-CKD-severity)" to both `flow-nephrologist` and
   `flow-ckm` (both hold that source locally), asking whichever can confirm to supersede endocrinology's
   abstract-level citation before Wave 3.
8. After `flow-ckm` independently verified via 4 sources that item 7's question resolves to THREE distinct
   papers (not two, and with a corrected PMID→journal mapping), relayed the corrected mapping to
   `flow-endocrinologist`, `flow-nephrologist`, and `flow-source-librarian`, and confirmed closure with
   `flow-ckm` — see "Resolution" subsection above for full detail.
9. On `flow-source-librarian` confirming the CJASN DOI and pulling abstract-level numbers, relayed both to
   `flow-endocrinologist` (citation fix + numbers to use) and `flow-nephrologist` (FYI).
10. On `flow-endocrinologist` independently corroborating `SELECT-FLOW-SOUL-POOLED-2026` via Europe PMC,
    relayed the second-source confirmation and retrieval route to `flow-methodologist` and `flow-trialist`.
11. On `flow-trialist` completing its self-initiated Wave 2 review of nephrology, relayed the one exact
    correction (AE-vs-overall discontinuation mislabel) to `flow-nephrologist`, along with two other review
    findings (Table 2 fully resolved; eGFR/UACR interaction-P GAP genuinely absent, recommend closing).

These are coordination relays only (naming exact files/sources per the ORCHESTRATION.md message protocol) —
no claim adjudication, no numbered-deliverable writing.

## Status / handoff

- **State: Wave 0 CROSS_SESSION_TEST complete — 6/6 replies received**
  (`flow-trialist`, `flow-endocrinologist`, `flow-nephrologist`, `flow-ckm`, `flow-source-librarian`,
  `flow-methodologist`), all READY=yes with confirmed owned paths. **4/6 lane files reported complete:**
  `flow-source-librarian` (01), `flow-trialist` (02, commit `6065ece` on `worktree-trialist-stats-lane`),
  `flow-endocrinologist` (04, commit `8c2dcf0`), and `flow-methodologist` (06, pushed on
  `worktree-flow-methodologist-lane06`) — each on session-specific worktree branches, the same isolation
  pattern this director session is using. `flow-nephrologist` (03) and `flow-ckm` (05) confirmed READY and
  were continuing their memos as of their replies; no completion report received from those two yet. **Wave 2
  has begun organically:** `flow-trialist` has already completed and pushed its fixed-pairing peer review of
  nephrology (`cross_reviews/02_trialist_reviews_nephrology.md`, commit `c492125`) — see dedicated subsection
  above.
- **Cross-lane items surfaced and closed out or handed off this wave:**
  (a) **FLOW Table 2 OCR-scramble** — independently hit by trialist and nephrologist, converging on the same
  PDF-page-transcribed numbers; relayed to librarian and folded into lane 01 §5. Resolved/tracked.
  (b) **Pre-FLOW glycemia/BP/weight mediation** — resolved by methodologist with exact Mann et al. 2021
  figures (see actions 5 above) and relayed to endocrinology + nephrology; both already leaning toward
  "suggestive, not strongly supported" per CLAUDE.md rule 7, now with numbers to cite directly. Closed.
  (c) **Three unverified 2026 guideline items** (KDIGO 2026 draft, ADA 2026 CKD chapter wording, AHA/ACC/ADA/
  ASN CKM guideline sequencing text) — flagged by CKM as fetch-blocked; open, appropriate for librarian/
  Wave 5 red-team follow-up with alternate fetch routes, not a numeric conflict.
  (d) **`SELECT-FLOW-SOUL-POOLED-2026` fulltext** — trialist declined (scope), methodologist picked it up and
  retrieved a structured abstract (N=30,787; primary composite HR 0.84 [0.77–0.91]; kidney-specific composite
  HR 0.80 [0.69–0.92]; PMID 42567173) with its own interpretive claim graded hypothesis-generating; relayed to
  trialist as an optional cross-check (action 6). Abstract-level only — full tables/appendix still
  unretrieved; open for Wave 3 if a lane pulls the full text.
- **CLAUDE.md updated mid-Wave-0** (on disk, after this director's original dispatch): adds MCP
  source-discovery preference, no-Sci-Hub rule, `sources/retrieved/cache/` convention, and an API-key handling
  rule for LlamaParse. This session is operating under the updated file; flagged in the librarian reply entry
  above for visibility to any lane that cached a source before the update landed.
- **Next action for this (director) session:** on resume, confirm the remaining two lane files (nephrology 03,
  CKM 05) have landed complete (endocrinology 04 already reported complete but has an outstanding citation fix
  to confirm — see the PMID 41706532 resolution above), verify the open items above at Wave 3 — (c) guideline
  fetch-blocks, (d) SELECT-FLOW-SOUL pooled-abstract full text, (e) CJASN DOI resolver check — and once all six
  lanes are confirmed complete, prepare Wave 2 cross-examination pairing per the fixed assignments in
  `ORCHESTRATION.md` (trialist↔nephrology, endocrinology↔CKM, methodologist on combination/causal claims,
  librarian auditing citations across all lanes). Wave 2 assignment itself was explicitly out of scope for
  this turn and has not been dispatched.
- **Not yet done (by design, out of scope for Wave 0/1):** no numbered deliverables (01-16), no
  `SOURCE_LEDGER.csv`, no conflict resolution/adjudication, no synthesis. `12_EVIDENCE_GAPS_AND_CONTROVERSIES.md`
  and `15_CLAIM_EVIDENCE_MAP.md` remain for Wave 3 once all lane memos and Wave 2 cross-reviews exist.
- **Files written this turn:** this file only (`orchestration/DIRECTOR_WAVE0.md`, in worktree
  `flow-director-wave0`).
